A long-term phase II clinical study of valbenazine for the treatment of Tourette Syndrome.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Valbenazine (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 08 Dec 2017 Status changed from recruiting to completed.
- 05 Aug 2016 New trial record